Sarepta Therapeutics Inc (SRPT)
Activity ratios
Short-term
Turnover ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inventory turnover | 0.44 | 0.42 | 0.38 | 0.44 | 0.47 | 0.56 | 0.62 | 0.71 | 0.69 | 0.64 | 0.60 | 0.53 | 0.52 | 0.30 | 0.29 | 0.30 | 0.27 | 0.26 | 0.30 | 0.33 |
| Receivables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Payables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Working capital turnover | 0.81 | 0.83 | 0.75 | 0.76 | 0.65 | 0.55 | 0.51 | 0.50 | 0.48 | 0.43 | 0.43 | 0.37 | 0.33 | 0.36 | 0.33 | 0.30 | 0.26 | 0.25 | 0.21 | 0.18 |
The analysis of Sarepta Therapeutics Inc's activity ratios reveals the following trends:
1. Inventory Turnover: The inventory turnover ratio shows a fluctuating trend over the analyzed periods, with a gradual increase from 0.33 in March 2020 to 0.44 in March 2024, indicating that the company's ability to sell through its inventory has improved over time.
2. Receivables Turnover: The data provided does not include information on receivables turnover. Therefore, it is difficult to assess the efficiency of the company in collecting payments from its customers.
3. Payables Turnover: Similarly, the data does not include information on payables turnover, making it challenging to evaluate how effectively the company is managing its outstanding payments to suppliers.
4. Working Capital Turnover: The working capital turnover ratio exhibits an increasing trend from 0.18 in March 2020 to 0.81 in December 2024. This indicates that the company is generating more revenue per dollar of working capital invested, reflecting improved efficiency in utilizing its working capital resources.
In conclusion, while Sarepta Therapeutics Inc has shown improvements in managing its inventory and working capital efficiency over the analyzed periods, more information on receivables and payables turnover is required to provide a comprehensive assessment of the company's overall activity performance.
Average number of days
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Days of inventory on hand (DOH) | days | 835.02 | 861.79 | 958.33 | 821.89 | 783.83 | 650.26 | 591.95 | 515.29 | 531.82 | 572.86 | 610.44 | 684.28 | 700.34 | 1,200.46 | 1,237.34 | 1,199.92 | 1,335.80 | 1,420.87 | 1,201.68 | 1,106.07 |
| Days of sales outstanding (DSO) | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Number of days of payables | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Based on the provided data, Sarepta Therapeutics Inc's Days of Inventory on Hand (DOH) has shown a decreasing trend over the years. The company had a substantial DOH figure of 1,420.87 days in September 2020, which has significantly dropped to 835.02 days by December 2024. This indicates that the company has been able to manage its inventory more efficiently, reducing the number of days it takes to sell its inventory.
However, data on Days of Sales Outstanding (DSO) and Number of Days of Payables are not available for analysis, suggesting that the company might not disclose or track this information, limiting our ability to assess the effectiveness of the company's accounts receivable and accounts payable management.
Overall, the declining trend in Days of Inventory on Hand for Sarepta Therapeutics Inc is a positive sign, suggesting improved inventory management efficiency, which can potentially lead to better cash flow and profitability in the long run.
Long-term
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fixed asset turnover | — | — | — | — | — | — | — | 2.81 | 3.81 | 4.84 | 4.56 | 4.09 | 3.67 | 3.24 | 2.17 | 2.82 | 2.84 | 2.88 | 2.94 | 2.97 |
| Total asset turnover | 0.48 | 0.46 | 0.44 | 0.44 | 0.38 | 0.36 | 0.32 | 0.32 | 0.30 | 0.28 | 0.28 | 0.25 | 0.22 | 0.24 | 0.22 | 0.21 | 0.18 | 0.18 | 0.16 | 0.14 |
Sarepta Therapeutics Inc's Fixed Asset Turnover ratio has shown an improving trend over the years, indicating the company's ability to generate more revenue from its fixed assets. Starting from 2.97 in March 2020, the ratio increased steadily to a peak of 4.84 in September 2022, before dropping to 3.81 by December 2022. It further declined to 2.81 by March 2023, possibly suggesting a decrease in the efficiency of utilizing fixed assets.
On the other hand, the Total Asset Turnover ratio has exhibited consistent growth from 0.14 in March 2020 to 0.48 by December 2024. This indicates that Sarepta Therapeutics has been effectively utilizing its total assets to generate sales and revenue. The increasing trend in this ratio reflects the company's efficiency in managing its assets to drive sales growth over the years.
Overall, Sarepta Therapeutics Inc's long-term activity ratios suggest a mix of efficiency levels in utilizing both fixed and total assets. The company should continue to monitor and improve its asset turnover ratios to ensure optimal utilization and productivity in the future.